

Cytiva and Pall Corporation investing 1.5 billion USD over two years to meet growing demand for biotechnology solutions

Major investments are expanding manufacturing capacity for life sciences products at 13 Cytiva and Pall Corporation sites helping to meet customer demand.

New sites opening in US and UK to realize regional manufacturing models. Overall, the companies plan to hire 2000 full-time associates over the next two years.

Investment follows five strategic acquisitions made by the companies this year and is in addition to Cytiva's continuing capacity investments estimated at 500 million USD through 2022.

July 27, 2021

The companies are investing, in USD:

400+ million

in cell culture media — in liquid or powder form this is used to grow and cultivate cells before they are purified — expand operations in US, UK and Austria.

300+ million

in single-use technologies — including bioreactor bags for growing cells used to make personalized medicines and syringe filters for scientific research — expand operations in US and the UK as well as fitting out a new facility in Cardiff, Wales.

200+ million

for continuing expansion work in Cytiva and Pall Corporation's sites across Europe, US and Asia-Pacific.

600+ million

in chromatography resins — media for analyzing or purifying biomolecules — establishing a new manufacturing site in the US to open in the future.

Investing over 1.5 billion USD

Hiring 2000+

New roles to be filled over the next two years globally.

